Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Chronic virus infection drives CD8 T cell-mediated thymic destruction and impaired negative selection.

Elsaesser HJ, Mohtashami M, Osokine I, Snell LM, Cunningham CR, Boukhaled GM, McGavern DB, Zúñiga-Pflücker JC, Brooks DG.

Proc Natl Acad Sci U S A. 2020 Mar 10;117(10):5420-5429. doi: 10.1073/pnas.1913776117. Epub 2020 Feb 24.

PMID:
32094187
2.

Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials.

Gadalla R, Noamani B, MacLeod BL, Dickson RJ, Guo M, Xu W, Lukhele S, Elsaesser HJ, Razak ARA, Hirano N, McGaha TL, Wang B, Butler M, Guidos CJ, Ohashi PS, Siu LL, Brooks DG.

Front Oncol. 2019 May 17;9:415. doi: 10.3389/fonc.2019.00415. eCollection 2019.

3.

Correction: CRACR2A-Mediated TCR Signaling Promotes Local Effector Th1 and Th17 Responses.

Woo JS, Srikanth S, Kim KD, Elsaesser H, Lu J, Pellegrini M, Brooks DG, Sun Z, Gwack Y.

J Immunol. 2019 Jul 1;203(1):293. doi: 10.4049/jimmunol.1900492. Epub 2019 May 24. No abstract available.

PMID:
31127031
4.

CD8+ T Cell Priming in Established Chronic Viral Infection Preferentially Directs Differentiation of Memory-like Cells for Sustained Immunity.

Snell LM, MacLeod BL, Law JC, Osokine I, Elsaesser HJ, Hezaveh K, Dickson RJ, Gavin MA, Guidos CJ, McGaha TL, Brooks DG.

Immunity. 2018 Oct 16;49(4):678-694.e5. doi: 10.1016/j.immuni.2018.08.002. Epub 2018 Oct 9.

5.

CRACR2A-Mediated TCR Signaling Promotes Local Effector Th1 and Th17 Responses.

Woo JS, Srikanth S, Kim KD, Elsaesser H, Lu J, Pellegrini M, Brooks DG, Sun Z, Gwack Y.

J Immunol. 2018 Aug 15;201(4):1174-1185. doi: 10.4049/jimmunol.1800659. Epub 2018 Jul 9. Erratum in: J Immunol. 2019 Jul 1;203(1):293.

6.

A CD103+ Conventional Dendritic Cell Surveillance System Prevents Development of Overt Heart Failure during Subclinical Viral Myocarditis.

Clemente-Casares X, Hosseinzadeh S, Barbu I, Dick SA, Macklin JA, Wang Y, Momen A, Kantores C, Aronoff L, Farno M, Lucas TM, Avery J, Zarrin-Khat D, Elsaesser HJ, Razani B, Lavine KJ, Husain M, Brooks DG, Robbins CS, Cybulsky M, Epelman S.

Immunity. 2017 Nov 21;47(5):974-989.e8. doi: 10.1016/j.immuni.2017.10.011.

7.

Purging Exhausted Virus-Specific CD8 T Cell Phenotypes by Somatic Cell Reprogramming.

Chan J, Kim PY, Kranz E, Nagaoka Y, Lee Y, Wen J, Elsaesser HJ, Qin M, Brooks DG, Ringpis GE, Chen ISY, Kamata M.

AIDS Res Hum Retroviruses. 2017 Nov;33(S1):S59-S69. doi: 10.1089/aid.2017.0161.

8.

Overcoming CD4 Th1 Cell Fate Restrictions to Sustain Antiviral CD8 T Cells and Control Persistent Virus Infection.

Snell LM, Osokine I, Yamada DH, De la Fuente JR, Elsaesser HJ, Brooks DG.

Cell Rep. 2016 Sep 20;16(12):3286-3296. doi: 10.1016/j.celrep.2016.08.065.

9.

Type I and Type II Interferon Coordinately Regulate Suppressive Dendritic Cell Fate and Function during Viral Persistence.

Cunningham CR, Champhekar A, Tullius MV, Dillon BJ, Zhen A, de la Fuente JR, Herskovitz J, Elsaesser H, Snell LM, Wilson EB, de la Torre JC, Kitchen SG, Horwitz MA, Bensinger SJ, Smale ST, Brooks DG.

PLoS Pathog. 2016 Jan 25;12(1):e1005356. doi: 10.1371/journal.ppat.1005356. eCollection 2016 Jan.

10.

Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection.

Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, de la Torre JC, Nimmerjahn F, Brooks DG.

Immunity. 2015 Feb 17;42(2):379-390. doi: 10.1016/j.immuni.2015.01.005. Epub 2015 Feb 10.

11.

Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.

Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, Winzeler B, Bingisser R, Elsaesser H, Drozdov D, Arici B, Urwyler SA, Refardt J, Tarr P, Wirz S, Thomann R, Baumgartner C, Duplain H, Burki D, Zimmerli W, Rodondi N, Mueller B, Christ-Crain M.

Lancet. 2015 Apr 18;385(9977):1511-8. doi: 10.1016/S0140-6736(14)62447-8. Epub 2015 Jan 19.

PMID:
25608756
12.

Corticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trial.

Blum CA, Nigro N, Winzeler B, Suter-Widmer I, Schuetz P, Briel M, Bingisser R, Zimmerli W, Ullmer E, Elsaesser H, Tarr P, Wirz S, Thomann R, Hofmann E, Rodondi N, Duplain H, Burki D, Mueller B, Christ-Crain M.

Trials. 2014 Jun 28;15:257. doi: 10.1186/1745-6215-15-257.

13.

Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection.

Osokine I, Snell LM, Cunningham CR, Yamada DH, Wilson EB, Elsaesser HJ, de la Torre JC, Brooks D.

Proc Natl Acad Sci U S A. 2014 May 20;111(20):7409-14. doi: 10.1073/pnas.1401662111. Epub 2014 May 5.

14.

Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses.

Gillespie EJ, Ho CL, Balaji K, Clemens DL, Deng G, Wang YE, Elsaesser HJ, Tamilselvam B, Gargi A, Dixon SD, France B, Chamberlain BT, Blanke SR, Cheng G, de la Torre JC, Brooks DG, Jung ME, Colicelli J, Damoiseaux R, Bradley KA.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):E4904-12. doi: 10.1073/pnas.1302334110. Epub 2013 Nov 4.

15.

Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, Aronow BJ, Karp CL, Brooks DG.

Science. 2013 Apr 12;340(6129):202-7. doi: 10.1126/science.1235208.

16.

Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity.

Kidani Y, Elsaesser H, Hock MB, Vergnes L, Williams KJ, Argus JP, Marbois BN, Komisopoulou E, Wilson EB, Osborne TF, Graeber TG, Reue K, Brooks DG, Bensinger SJ.

Nat Immunol. 2013 May;14(5):489-99. doi: 10.1038/ni.2570. Epub 2013 Apr 7.

17.

Emergence of distinct multiarmed immunoregulatory antigen-presenting cells during persistent viral infection.

Wilson EB, Kidani Y, Elsaesser H, Barnard J, Raff L, Karp CL, Bensinger S, Brooks DG.

Cell Host Microbe. 2012 May 17;11(5):481-91. doi: 10.1016/j.chom.2012.03.009.

18.

Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells.

Fahey LM, Wilson EB, Elsaesser H, Fistonich CD, McGavern DB, Brooks DG.

J Exp Med. 2011 May 9;208(5):987-99. doi: 10.1084/jem.20101773. Epub 2011 May 2.

19.

IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection.

Brooks DG, Walsh KB, Elsaesser H, Oldstone MB.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3018-23. doi: 10.1073/pnas.0914500107. Epub 2010 Jan 26.

20.

IL-21 is required to control chronic viral infection.

Elsaesser H, Sauer K, Brooks DG.

Science. 2009 Jun 19;324(5934):1569-72. doi: 10.1126/science.1174182. Epub 2009 May 7. Erratum in: Science. 2009 Aug 21;325(5943):946.

21.

IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection.

Brooks DG, Ha SJ, Elsaesser H, Sharpe AH, Freeman GJ, Oldstone MB.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20428-33. doi: 10.1073/pnas.0811139106. Epub 2008 Dec 15.

22.

IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection.

Brooks DG, Lee AM, Elsaesser H, McGavern DB, Oldstone MB.

J Exp Med. 2008 Mar 17;205(3):533-41. doi: 10.1084/jem.20071948. Epub 2008 Mar 10.

23.

Bone marrow transplantation abolishes inhibition of arteriogenesis in placenta growth factor (PlGF) -/- mice.

Scholz D, Elsaesser H, Sauer A, Friedrich C, Luttun A, Carmeliet P, Schaper W.

J Mol Cell Cardiol. 2003 Feb;35(2):177-84.

PMID:
12606258
24.

Late results of prosthetic valve replacement for aortic regurgitation and the prognostic significance of the end-diastolic and regurgitated blood volumes.

Skupin M, Klepzig H, Beyersdorf F, Elsaesser H, Kaltenbach M, Satter P.

Thorac Cardiovasc Surg. 1988 Dec;36(6):326-31.

PMID:
2976538

Supplemental Content

Loading ...
Support Center